SIRT2 and central nervous system cancer: Inhibitors targeting SIRT2 induce epigenome reprogramming in ATRX-deficient glioma models by modifying H3K27ac and H4K16ac marks on chromatin and causing genome-wide changes via enhancer-associated modifications, promoting senescence in the ATRX-deficient glioma model system (Malgulwar et al., 2024).